MIDAZOLAM
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Midazolam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity by binding to the benzodiazepine site on GABA-A receptors, enhancing GABA's inhibitory effects, leading to increased chloride ion conductance, hyperpolarization, and neuronal inhibition.
| Metabolism | Midazolam is extensively metabolized in the liver via CYP3A4 isoenzymes to active metabolites (1-hydroxymidazolam and 4-hydroxymidazolam), which undergo glucuronidation. |
| Excretion | Renal: approximately 45-57% as metabolites (primarily 1-hydroxymidazolam glucuronide) and <1% unchanged; fecal: 2-10% via biliary excretion. |
| Half-life | Terminal elimination half-life: 1.5-2.5 hours in healthy adults; prolonged in elderly (5-6 hours), obesity, hepatic cirrhosis (up to 20 hours), and critical illness. |
| Protein binding | 97% bound to albumin. |
| Volume of Distribution | Vd: 1-3 L/kg; increased in obesity (up to 3-5 L/kg) and critically ill patients, reflecting extensive tissue distribution. |
| Bioavailability | Oral: 40-50% (first-pass metabolism); IM: >90%; Intranasal: approximately 50-80%; Rectal: approximately 40-50%. |
| Onset of Action | IV: 1-2 minutes; IM: 5-15 minutes; Oral: 15-30 minutes; Intranasal: 10-15 minutes; Rectal: 10-20 minutes. |
| Duration of Action | IV: 20-30 minutes (amnesia up to 1 hour); IM: 2-6 hours (dose-dependent); Oral: 2-6 hours; recovery may be prolonged in elderly or hepatic impairment. |
| Molecular Weight | 325.77 |
IV: 0.5-2 mg initial, titrate by 0.5-1 mg increments every 2-3 min; typical total 2.5-5 mg. IM: 0.07-0.08 mg/kg (usual 5 mg). Oral: 7.5-15 mg as a single premedication dose.
| Dosage form | SPRAY |
| Renal impairment | GFR ≥ 30 mL/min: no adjustment. GFR 10-29 mL/min: consider 25% dose reduction. GFR < 10 mL/min: avoid long-term use; consider 50% dose reduction or alternative. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: use with caution; reduce dose by 75% or consider alternative. |
| Pediatric use | IV sedation: 0.05-0.1 mg/kg initial, max 0.15-0.2 mg/kg total. Oral premedication: 0.25-1 mg/kg (max 20 mg). Intranasal: 0.3 mg/kg (max 10 mg). Rectal: 0.3-0.5 mg/kg (max 20 mg). |
| Geriatric use | Initial dose: 0.5 mg IV; titrate slowly with 0.5 mg increments. Max dose: 1.5 mg total. Oral: 3-7.5 mg as a single dose. Avoid doses > 7.5 mg due to increased risk of oversedation and respiratory depression. |
| 1st trimester | Teratogenic effects have been observed in animal studies; human data limited. Use only if clearly needed, preferably in late pregnancy, as the drug crosses the placenta. Midazolam is not recommended in the first trimester unless benefits outweigh risks. |
| 2nd trimester | Potential risks include fetal CNS depression, hypotonia, and withdrawal symptoms if used chronically. Consider alternative agents; use with caution and only if necessary. |
| 3rd trimester | May cause neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near delivery. Avoid use during labor and delivery, especially premature infants. |
Clinical note
CNS depressants including alcohol and opioids increase sedation risk Can cause profound respiratory depression and hypotension.
| Placental transfer | Midazolam crosses the placenta rapidly with umbilical cord/maternal plasma concentration ratios reported around 0.6-0.7. Fetal exposure is significant and may cause sedation, hypothermia, and respiratory depression based on dose and timing. |
| Breastfeeding |
■ FDA Black Box Warning
Midazolam is associated with respiratory depression, apnea, and respiratory arrest. Concomitant use with other CNS depressants (e.g., opioids, alcohol) increases risk. Should be administered only by trained personnel in a setting equipped for monitoring and resuscitation.
| Common Effects | anesthesia |
| Serious Effects |
Acute narrow-angle glaucomaKnown hypersensitivity to midazolam or any benzodiazepineSevere respiratory insufficiency (e.g., COPD, sleep apnea) unless on ventilatory supportMyasthenia gravisSevere hepatic impairment (Child-Pugh class C)Use in premature infants and neonates (especially for sedation in ICU) due to increased risk of death when used with fentanyl
| Precautions | Respiratory depression and apnea risk, especially in elderly, debilitated, or patients with COPD, Hypotension and cardiac arrest risk in critically ill patients, Paradoxical reactions (e.g., agitation, aggression), Potential for abuse and dependence (Schedule IV controlled substance), Use with caution in patients with hepatic or renal impairment, Risk of withdrawal symptoms with abrupt discontinuation, Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death |
Loading safety data…
| Midazolam enters breast milk in low amounts; however, due to risk of infant sedation and respiratory depression, caution is advised. Monitor infant for signs of drowsiness, feeding difficulties, or respiratory issues. Alternative agents with better safety profiles may be preferred. |
| Lactation Rating | L3 (Limited Data - Possibly Hazardous) |
| Teratogenic Risk | First trimester: Limited human data, but no consistent pattern of major malformations; benzodiazepines are associated with a small increased risk of oral cleft (about 0.2-0.4% absolute risk). Second and third trimesters: Risk of floppy infant syndrome, respiratory depression, hypotonia, and withdrawal symptoms in neonates, especially with chronic or high-dose exposure near term. |
| Fetal Monitoring | Monitor maternal sedation, respiratory rate, and oxygen saturation during administration. For chronic use or high doses near term, monitor fetal heart rate during labor and assess neonatal Apgar scores, respiratory status, hypotonia, and withdrawal symptoms (irritability, feeding difficulties) after birth. |
| Fertility Effects | No specific data on human fertility impairment; animal studies with benzodiazepines have not shown significant effects on fertility. However, benzodiazepines may influence hypothalamic-pituitary-gonadal axis, but relevance is unknown. |
| Food/Dietary | No significant food interactions. Avoid grapefruit juice as it may increase midazolam levels via CYP3A4 inhibition. |
| Clinical Pearls | Midazolam is a short-acting benzodiazepine with rapid onset and a high potency. It is commonly used for procedural sedation, anesthesia induction, and ICU sedation. Notably, its amnestic effect is more pronounced than other benzodiazepines. Use caution in elderly and hepatically impaired patients due to reduced clearance. Flumazenil is the reversal agent. Respiratory depression risk is dose-dependent and potentiated by opioids. |
| Patient Advice | This medication causes drowsiness and dizziness; do not drive or operate heavy machinery after taking it. · Avoid alcohol and other CNS depressants while on this medication. · You may experience temporary amnesia after administration; do not make important decisions until fully recovered. · If you are pregnant or breastfeeding, inform your healthcare provider before use. · Take this medication exactly as prescribed; do not increase the dose or frequency without consulting your doctor. |